In a Nutshell
TB-500 is not FDA-approved, and controlled human evidence does not establish that it accelerates tendon, muscle or soft-tissue healing.
TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. It is marketed almost entirely for recovery — soft tissue, tendon, muscle — and is most often sold stacked with BPC-157.
The distinction that gets lost in the marketing: thymosin beta-4 itself has been studied in humans; TB-500 as sold is a fragment of it, and the two are not interchangeable. FDA's own listing refers to it precisely as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" 1.
TB-500 is not an FDA-approved drug. On July 23, 2026 an FDA advisory committee voted 8 yes / 6 no / 1 abstention on each form to recommend it for the 503A Bulks List, contrary to the conclusions presented by FDA staff reviewers. FDA has not acted on that recommendation.
What TB-500 Is
Thymosin beta-4 is a 43-amino-acid peptide found throughout the body, with a well-described role in regulating actin — the protein cells use to change shape and move. Cell migration is fundamental to wound healing, which is the basis of the therapeutic interest.
TB-500 is the N-acetylated LKKTETQ heptapeptide, corresponding to residues 17–23 of thymosin beta-4. That precision matters: full-length thymosin beta-4, non-acetylated LKKTETQ and N-acetylated TB-500 are three different test articles, and FDA has said acetylation can change a peptide's charge, hydrophobicity, stability and binding — so findings from the parent peptide or the non-acetylated fragment cannot be assumed to establish TB-500's pharmacology.
FDA identified no in-vivo study showing TB-500 promotes wound healing. In one in-vitro scratch assay, TB-500 free base did not significantly improve wound closure, though a shorter metabolite produced a small effect. Whether TB-500 itself drives clinically meaningful cell migration or repair is unknown.
Current FDA and Compounding Status
TB-500 is not approved by FDA for any use.
It appears on FDA's list of bulk substances "nominated but withdrawn" — previously in Category 2, until the nominator withdrew the nomination 1. Even so, FDA elected to continue evaluating the free-base and acetate forms on its own initiative — which is why the substance still came before the committee.
This is not FDA clearance, and removal from Category 2 does not by itself make a substance eligible for compounding. Eligibility runs through one of three statutory routes under Section 503A — an applicable USP/NF monograph, being a component of an FDA-approved drug, or the 503A Bulks List — and every other 503A requirement still applies. For this substance FDA found no applicable USP/NF monograph and no FDA-approved drug containing it, so the 503A Bulks List is the only route identified in FDA's current review. The committee's vote did not add it to that list and changed no present authority to compound it.
FDA's stated concern is that compounded TB-500 "may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation as well as peptide-related impurities," and that FDA "has not identified any human exposure data" for products containing it — leaving the agency without the information to judge whether it would cause harm 1.
"No human exposure data identified" is a stronger statement than it first appears. See the FDA peptide status page for the full picture.
What the Evidence Actually Shows
Evidence tier: C.
Preclinical work on thymosin beta-4 — largely in animal models of cardiac, corneal and dermal injury — is real and has been ongoing for years. Some clinical work on thymosin beta-4 in specific indications has been undertaken by pharmaceutical developers.
None of that establishes that TB-500, the fragment, sold as a research chemical, injected without supervision, at doses derived from forums, does anything beneficial in humans. There are no published randomized controlled trials of TB-500 for recovery, tendon healing or athletic performance.
The recurring marketing move in this category is to cite thymosin beta-4 literature under a TB-500 heading. Watch for it.
Safety and What Is Unknown
- Human safety data: essentially absent. FDA's position is that it has identified no human exposure data at all 1
- Long-term effects: unknown
- Carcinogenicity: unstudied. No long-term carcinogenicity study has been conducted, and no human cancer signal has been established. Note also that the cell-migration mechanism TB-500 is marketed on has not itself been established for the acetylated substance — so the usual mechanism-to-cancer argument has no firm footing at either end
- Immunogenicity: FDA's stated concern regarding aggregation and peptide-related impurities
- Pregnancy and breastfeeding: no data; not appropriate
- Product risk: most TB-500 in circulation is research-grade, carrying risks of contamination, incorrect dose and mislabeled contents independent of the substance — see peptide sourcing and quality
Red Flags — Seek Care Now
- Fever, spreading redness, swelling or pus at an injection site
- Difficulty breathing, facial or throat swelling, widespread hives — call 911
- Chest pain or palpitations
- New or rapidly changing lumps, or unexplained weight loss
Tell any treating clinician what you have used.
Prohibited in Sport
TB-500 is prohibited under World Anti-Doping Agency rules and by organizations following them, including USADA and the NCAA — regardless of FDA status. Confirm with your governing body directly.
On Dosing
This page does not provide dosing protocols. There is no established human dose for TB-500 because no human dose-finding study has been completed. Circulating protocols are extrapolated or copied between forums and applied to products of unverified concentration. If you are using it regardless, tell your clinician so someone trained is monitoring.
What You Can Do About It
If the goal is recovery from a specific injury, that injury deserves a diagnosis. Tendon problems in particular are commonly mismanaged because "tendinitis" is assumed where the actual pathology differs and calls for different loading, rehabilitation or imaging. Slow recovery generally is often downstream of something measurable — thyroid function, vitamin D, iron studies, sleep quality, protein intake or body composition.
Get Started with JumpstartMD
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, delivered by licensed clinicians you see face-to-face — in person at 14 California locations or online across California — starting with a clinical assessment that includes 60-biomarker lab screening and InBody® body composition scanning. If slow recovery is what brought you here, that assessment can identify some of its contributors and indicate when targeted injury evaluation, imaging or specialist referral is needed — it cannot determine every cause from laboratory testing alone. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Can you get TB-500 on prescription?
TB-500 is not an FDA-approved drug, and FDA has not acted on the July 2026 advisory recommendation.
If the symptom or goal that led you here has not been evaluated, our clinicians can assess the relevant causes and evidence-based options — that assessment does not assume another peptide is the answer. Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- BPC-157 — the peptide most often stacked with TB-500
- Are Peptides Legal in the US? — the July 2026 vote in full
- How to Tell If a Peptide Is Legitimate
- Peptide Therapy: What It Is and Who It's For
Frequently Asked Questions
What is TB-500 used for?
It is marketed for recovery — soft tissue, tendon and muscle healing — based on the role of the parent protein thymosin beta-4 in cell migration and wound repair. It is not approved for any use, and there are no published controlled human trials supporting these uses.
What is the difference between BPC-157 and TB-500?
They are different peptides with different proposed mechanisms. BPC-157 is associated with angiogenesis and growth-factor signaling; TB-500 with actin regulation and cell migration. They are often sold together as a recovery stack. Neither is FDA-approved, both received favorable advisory votes in July 2026, and neither has an adequately reported, peer-reviewed randomized trial establishing efficacy (BPC-157 has one abstract-only 2005 enema trial in colitis; TB-500 has none).
Is TB-500 FDA approved?
No. An FDA advisory committee voted 8–6 in July 2026 to recommend it for the compounding bulks list, contrary to the conclusions presented by FDA staff reviewers. FDA has not acted, and compounding eligibility would not equal drug approval.
How quickly does TB-500 work?
There is no reliable answer. No controlled human trial has measured onset or effect for any indication, so timelines circulating online are anecdotal.
Is TB-500 safe?
Unknown. FDA states it has identified no human exposure data for products containing TB-500. That is an absence of evidence rather than evidence of harm — but it is a very thin basis for confidence, and it is separate from the contamination and dosing risks of unregulated products.
References
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- Regulatory Affairs Professionals Society, "FDA advisory committee backs two controversial peptides," Jul. 2026. [Online]. Available: https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html [Accessed: Jul. 25, 2026]. ↩
- The Hill, "FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists," Jul. 2026. [Online]. Available: https://thehill.com/homenews/5987510-fda-committee-votes-peptides/ [Accessed: Jul. 25, 2026]. ↩
- World Anti-Doping Agency, "The 2026 Prohibited List — World Anti-Doping Code International Standard," in effect 1 Jan. 2026, §S2.3 Growth Factors and Growth Factor Modulators. [Online]. Available: https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (landing page: https://www.wada-ama.org/en/prohibited-list) [Accessed: Oct. 5, 2026]. ↩
- A. L. Goldstein, E. Hannappel, H. K. Kleinman, "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues," Trends in Molecular Medicine, vol. 11, no. 9, pp. 421-9, Sep. 2005, [Online]. Available: https://doi.org/10.1016/j.molmed.2005.07.004. PMID: 16099219. [Accessed: Jul. 25, 2026]. ↩